Meta-analysis of the comparative efficacy and safety of adjuvant treatment to Levodopa in later Parkinson's disease

Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J. J. Van Hilten, Keith Wheatley, Richard Gray

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)


Levodopa initially provides good symptomatic control of the symptoms of Parkinson's disease, but motor complications often develop after long-term use. Other classes of antiparkinsonian drugs including dopamine agonists, catechol-O-methyl transferase inhibitors, or monoamine oxidase type B inhibitors are then added as adjuvant therapy. It is unclear whether one class of drug is more effective than another. This meta-analysis evaluates the comparative benefits and risks of these agents as adjuvant treatment in Parkinson's disease patients with motor complications.
Original languageEnglish
Pages (from-to)587-598
Number of pages12
JournalMovement Disorders
Issue number4
Publication statusPublished - Mar 2011

Cite this